These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16865308)

  • 1. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.
    Sakellariou GT; Chatzigiannis I
    Clin Rheumatol; 2007 Jun; 26(6):950-2. PubMed ID: 16865308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.
    El Mansouri L; Couchouron T; Le Roux G; Dugast C; Burtin F; Albert JD; Perdriger A; Hassouni NH; Chalès G
    Joint Bone Spine; 2009 Jul; 76(4):421-3. PubMed ID: 19457692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
    Andreu JL; Otón T; Sanz J
    Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
    Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
    Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.
    Braun J; Sieper J; Breban M; Collantes-Estevez E; Davis J; Inman R; Marzo-Ortega H; Mielants H
    Ann Rheum Dis; 2002 Dec; 61 Suppl 3(Suppl 3):iii51-60. PubMed ID: 12381511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.
    Pérez-Alvarez R; Díaz-Lagares C; García-Hernández F; Lopez-Roses L; Brito-Zerón P; Pérez-de-Lis M; Retamozo S; Bové A; Bosch X; Sanchez-Tapias JM; Forns X; Ramos-Casals M;
    Medicine (Baltimore); 2011 Nov; 90(6):359-371. PubMed ID: 22033451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of ankylosing spondylitis with anti-TNFalpha agents].
    Bontoux D; Azaïs I; Goupille P
    Bull Acad Natl Med; 2006; 190(4-5):981-92; discussion 993-4. PubMed ID: 17195622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
    Sieper J; Braun J
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii58-61. PubMed ID: 11890656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
    Cohen JD; Ferreira R; Jorgensen C
    J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.